New Delhi: In a significant step towards strengthening India’s healthcare and pharmaceutical ecosystem, the Indian Pharmacopoeia Commission (IPC) under the Ministry of Health and Family Welfare has signed two important Memoranda of Understanding (MoUs) with the Pharmaceuticals & Medical Devices Bureau of India (PMBI) and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur.
These collaborations aim to improve drug quality assurance, pharmacovigilance systems, rational use of medicines, and advanced pharmaceutical research in the country.
IPC–PMBI MoU to Strengthen Quality and Safety of Jan Aushadhi Medicines
The MoU between IPC and PMBI is focused on enhancing the quality framework of medicines available through Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) across India.
Key highlights of the partnership include:
- Random quality testing of Jan Aushadhi medicine batches by IPC
- Promotion of the National Formulary of India (NFI) for rational drug use
- Strengthening pharmacovigilance systems under the Pharmacovigilance Programme of India (PvPI)
- Display of ADR reporting QR codes and toll-free helpline (1800-180-3024) at PMBJKs
- Encouraging adverse drug reaction (ADR) reporting for improved patient safety
- Joint training and awareness programmes for pharmacists and healthcare stakeholders
This collaboration is expected to significantly enhance medicines safety monitoring and public awareness across Jan Aushadhi centres nationwide.
Read also: Govt Introduces ₹5,000 Crore Incentive Scheme for Mining Reforms Under SASCI FY 2026–27
IPC–NIPER Hajipur Partnership to Advance Pharmaceutical Research
The second MoU between IPC and NIPER Hajipur focuses on strengthening research, innovation, and academic collaboration in pharmaceutical sciences.
NIPER Hajipur, an Institute of National Importance, will work closely with IPC in key areas such as:
- Joint research on impurity profiling, including genotoxic impurities like nitrosamines
- Development of analytical methods and quality control protocols
- Creation of reference standards for biologics, biosimilars, and advanced therapies such as cell and gene therapy products
- Strengthening pharmacopoeial standards for inclusion in the Indian Pharmacopoeia
The collaboration also includes:
- Faculty exchange programmes
- Shared access to advanced laboratory infrastructure
- Training workshops, seminars, and conferences
- Internship and fellowship opportunities for pharmacy students
- Joint research publications and academic material development
This partnership is expected to significantly enhance India’s capabilities in drug quality research and regulatory science.
Strengthening India’s Pharmaceutical Excellence and Patient Safety
Both MoUs reflect a broader national effort to strengthen India’s pharmaceutical ecosystem through quality assurance, innovation, and scientific collaboration. The initiatives align with ongoing efforts to improve patient safety, rational drug use, and regulatory excellence.
These partnerships are expected to further reinforce India’s position as a global hub for pharmaceutical quality standards, healthcare innovation, and public health advancement.
About Indian Pharmacopoeia Commission (IPC)
The Indian Pharmacopoeia Commission (IPC) is an autonomous institution under the Ministry of Health and Family Welfare responsible for setting standards for drugs in India and ensuring their quality, safety, and efficacy through the Indian Pharmacopoeia.
